Floatz logo

ETOPOSIDE

Hormone-resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversitySmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hormone-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3BBB
Abiraterone Acetate
Alliance for Clinical Trials in Oncology
Phase 3BB
Irinotecan
Roswell Park Cancer Institute
Phase 3BB
PREDNISONE TABLETS
University of California, Davis
Phase 3BB
Rebimastat
National Cancer Institute (NCI)
Phase 2B

View all 27 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →